Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
The post Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s appeared first on Business News.
Leaders agree a coordinated drawdown within four months as rising prices put pressure on households …
The £2 threshold was crossed as the group of advanced economies agreed to a substantial …
The rise in global oil prices has been pushing up the pump prices of petrol …
